Literature DB >> 18722174

Interaction between antibody-diversification enzyme AID and spliceosome-associated factor CTNNBL1.

Silvestro G Conticello1, Karuna Ganesh2, Kanmin Xue2, Mason Lu2, Cristina Rada2, Michael S Neuberger3.   

Abstract

Activation-induced deaminase (AID) deaminates deoxycytidine residues in immunoglobulin genes, triggering antibody diversification. Here, by use of two-hybrid and coimmunoprecipitation assays, we identify CTNNBL1 (also known as NAP) as an AID-specific interactor. Mutants of AID that interfere with CTNNBL1 interaction yield severely diminished hypermutation and class switching. Targeted inactivation of CTNNBL1 in DT40 B cells also considerably diminishes IgV diversification. CTNNBL1 is a widely expressed nuclear protein that associates with the Prp19 complex of the spliceosome, interacting with its CDC5L component. The results, therefore, identify residues in AID involved in its in vivo targeting and suggest they might act through interaction with CTNNBL1, giving possible insight into the linkage between AID recruitment and target-gene transcription.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18722174     DOI: 10.1016/j.molcel.2008.07.009

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  68 in total

1.  Histone chaperone Spt6 is required for class switch recombination but not somatic hypermutation.

Authors:  Il-mi Okazaki; Katsuya Okawa; Maki Kobayashi; Kiyotsugu Yoshikawa; Shimpei Kawamoto; Hitoshi Nagaoka; Reiko Shinkura; Yoko Kitawaki; Hisaaki Taniguchi; Tohru Natsume; Shun-Ichiro Iemura; Tasuku Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

Review 2.  Immunoglobulin class-switch DNA recombination: induction, targeting and beyond.

Authors:  Zhenming Xu; Hong Zan; Egest J Pone; Thach Mai; Paolo Casali
Journal:  Nat Rev Immunol       Date:  2012-06-25       Impact factor: 53.106

3.  GANP-mediated recruitment of activation-induced cytidine deaminase to cell nuclei and to immunoglobulin variable region DNA.

Authors:  Kazuhiko Maeda; Shailendra Kumar Singh; Kazufumi Eda; Masahiro Kitabatake; Phuong Pham; Myron F Goodman; Nobuo Sakaguchi
Journal:  J Biol Chem       Date:  2010-05-27       Impact factor: 5.157

Review 4.  Combinatorial mechanisms regulating AID-dependent DNA deamination: interacting proteins and post-translational modifications.

Authors:  Bao Q Vuong; Jayanta Chaudhuri
Journal:  Semin Immunol       Date:  2012-07-06       Impact factor: 11.130

Review 5.  Does DNA repair occur during somatic hypermutation?

Authors:  Huseyin Saribasak; Patricia J Gearhart
Journal:  Semin Immunol       Date:  2012-06-22       Impact factor: 11.130

6.  APOBEC3B and AID have similar nuclear import mechanisms.

Authors:  Lela Lackey; Zachary L Demorest; Allison M Land; Judd F Hultquist; William L Brown; Reuben S Harris
Journal:  J Mol Biol       Date:  2012-03-23       Impact factor: 5.469

Review 7.  Controlling somatic hypermutation in immunoglobulin variable and switch regions.

Authors:  Robert W Maul; Patricia J Gearhart
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

8.  Regulation of activation-induced deaminase stability and antibody gene diversification by Hsp90.

Authors:  Alexandre Orthwein; Anne-Marie Patenaude; El Bachir Affar; Alain Lamarre; Jason C Young; Javier M Di Noia
Journal:  J Exp Med       Date:  2010-11-01       Impact factor: 14.307

9.  The interaction between AID and CIB1 is nonessential for antibody gene diversification by gene conversion or class switch recombination.

Authors:  Zachary L Demorest; Donna A MacDuff; William L Brown; Scott G Morham; Leslie V Parise; Reuben S Harris
Journal:  PLoS One       Date:  2010-07-20       Impact factor: 3.240

10.  Immunoglobulin switch mu sequence causes RNA polymerase II accumulation and reduces dA hypermutation.

Authors:  Deepa Rajagopal; Robert W Maul; Amalendu Ghosh; Tirtha Chakraborty; Ahmed Amine Khamlichi; Ranjan Sen; Patricia J Gearhart
Journal:  J Exp Med       Date:  2009-05-11       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.